Drug Profile
AR 101 - Arava
Alternative Names: AR-101 - Arava; AR/101Latest Information Update: 19 Nov 2018
Price :
$50
*
At a glance
- Originator Arava Bio Tech
- Developer Arava Bio Tech; Cato Research
- Class Skin disorder therapies
- Mechanism of Action Epithelial cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Wounds
Most Recent Events
- 19 Nov 2018 No recent reports of development identified for phase-I/II for Wounds (In volunteers) in USA (Topical)
- 22 Jul 2016 Arava plans a phase II trial for Wounds in Israel (NCT02839226)
- 10 Nov 2015 Phase-I/II clinical trials in Wounds (In volunteers) in USA (Topical) (NCT02602184)